Dr Aloise Mabondzo is director of research at Commissariat à l’Energie Atomique (CEA)/Frédéric Joliot Institute and head of the Neurovascular Unit Research and Therapeutic Innovation laboratory (LENIT). Dr Mabondzo is internationally recognized in the development of cellular models to study the permeability of the human blood-brain barrier (BBB), predict the drug BBB passage and explore the therapeutic approaches for the treatment of cerebral diseases that we are facing (rare brain disorders, cerebrovascular disease, brain metastes).  As a neuroscientist, Dr Mabondzo aims to bridge the gap between experimental research and clinical therapy for cerebral diseases. His lab is currently developing brain organoids to complement in vivo animal studies in order to enhance the translatability of the preclinical animal studies and the understanding of brain-related disorders. Dr Aloïse Mabondzo is co-founder of a start-up CERES BRAIN THERAPEUTICS created in 2019 and dedicated to the development of treatments against rare diseases. Dr Aloïse Mabondzo was selected two years ago to receive the HEC Challenge Plus training, set up by the most prestigious French School of Economics to help developers of innovative projects with high growth potential build their business plans. Dr Mabondzo is also named as the inventor in nine patent families.